US 8809502
Mutated anti-CD22 antibodies with increased affinity to CD22-expressing leukemia cells
granted A61KA61K2039/505A61K47/6829
Quick answer
US patent 8809502 (Mutated anti-CD22 antibodies with increased affinity to CD22-expressing leukemia cells) held by The United States of America as Represented by the Secretary of the Department of Health and Human Services expires Mon Aug 14 2034 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.
Key facts
- Applicant
- The United States of America as Represented by the Secretary of the Department of Health and Human Services
- Grant date
- Tue Aug 19 2014 00:00:00 GMT+0000 (Coordinated Universal Time)
- Expiration
- Mon Aug 14 2034 00:00:00 GMT+0000 (Coordinated Universal Time)
- Claims
- 18
- CPC classes
- A61K, A61K2039/505, A61K47/6829, A61K47/6849, A61K47/6875